Chr. Hansen (Hørsholm, Denmark) and Caelus Health (Amsterdam) are teaming up to develop a “next generation” probiotic for the prevention and treatment of metabolic disease.
Caelus Health’s patented Eubacterium hallii CP-001 strain is at the center of the collaboration, which has shown potential at reducing insulin resistance in preclinical studies, according to a press release. E hallii CP-001 is currently in a phase I clinical study, but Chr. Hansen plans to take it a step further with the new deal.
“The objective of the collaboration between Chr. Hansen and Caelus Health is to develop a CP-001 product formulation that will allow for progression to a phase II clinical trial and a subsequent market introduction,” Chr. Hansen says.
Chr. Hansen will also develop pilot material and a production process for clinical trials which Caelus Health will then run, relating to the use of E hallii for “prevention and treatment of metabolic disease.”
“We are very pleased to announce this cooperation and are confident that Chr. Hansen has all the expertise and capabilities to develop an advanced formulation of CP-001, which we will further study in upcoming phase II clinical studies,” says Luc Sterkman, MD, CEO of Caelus. “This E. hallii-based product is the first of a series of microbiome-based products which Caelus plans to bring to the market.”
The agreement also marks an “important milestone” as the first of several human microbiome projects for Chr. Hansen, says Johan van Hylckama Vlieg, PhD, senior director of microbiome, Chr. Hansen.
“The collaboration with Caelus is in full alignment with our strategy to become the partner of choice for companies wanting to develop new generations of probiotic products and therapeutic microbes,” says van Hylckama Vlieg.
Nutritional Outlook Magazine